The number of type 2 inflammation comorbidities in atopic dermatitis or asthma is associated with work productivity and activity impairment (WPAI) and health-related quality of life (HRQoL)

Abstract Background Type 2 inflammation (T2I) plays a major role in atopic dermatitis (AD) and asthma, and is associated with work productivity and activity impairment (WPAI) and health-related quality of life (HRQoL). However, the cumulative effect of multiple T2I comorbidities remains unclear. We aimed to investigate whether an increased number of T2I comorbidities was associated with WPAI and HRQoL among individuals with AD or asthma and T2I comorbidities in Japan. Methods This retrospective observational study used commercially available data from the 2020 and 2021 Japan National Health and Wellness Surveys, and included individuals with self-reported AD/asthma. The primary outcome was to assess WPAI in each study cohort; secondary outcomes included assessing HRQoL. Results Among the analyzed individuals (AD, N = 957 in 2021; asthma, N = 746 in 2020), approximately half had ≥ 1 additional T2I comorbidity (hay fever, food allergy, asthma/AD, nasal polyps). Both cohorts had substantial overall WPAI (26.6–28.9% of patients). In the AD cohort, individuals with one, two, or three additional T2I comorbidities experienced 4.7%, 5.5%, and 12.1% more overall work impairment, respectively, than those with no comorbidities; the corresponding differences in the asthma cohort were 6.7%, 12.5%, and 13.9%, respectively. Concurrently, several components of HRQoL worsened progressively as the number and burden of T2I comorbidities increased. Conclusion Given that there is considerable correlation between the number of T2I comorbidities and WPAI and HRQoL, comprehensive management of T2I diseases may be crucial for patient care.

Authors

Institutions

Publication Details

Journal
Allergy Asthma and Clinical Immunology
Published
2026-11-13
DOI
https://doi.org/10.1186/s13223-026-01078-2
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The number of type 2 inflammation comorbidities in atopic dermatitis or asthma is associated with work productivity and activity impairment (WPAI) and health-related quality of life (HRQoL)

Yoshinori Sunaga, Kazuhiko Arima, Hiroyuki Nagase, Masato Ishida et al.
1 links
Allergy Asthma and Clinical Immunology
Dermatology and Skin Diseases
article

The number of type 2 inflammation comorbidities in atopic dermatitis or asthma is associated with work productivity and activity impairment (WPAI) and health-related quality of life (HRQoL)

Yoshinori Sunaga, Kazuhiko Arima, Hiroyuki Nagase, Masato Ishida, Shizuka Takashima, Akio Tanaka, Michika Mochizuki
article en

Abstract

Abstract Background Type 2 inflammation (T2I) plays a major role in atopic dermatitis (AD) and asthma, and is associated with work productivity and activity impairment (WPAI) and health-related quality of life (HRQoL). However, the cumulative effect of multiple T2I comorbidities remains unclear. We aimed to investigate whether an increased number of T2I comorbidities was associated with WPAI and HRQoL among individuals with AD or asthma and T2I comorbidities in Japan. Methods This retrospective observational study used commercially available data from the 2020 and 2021 Japan National Health and Wellness Surveys, and included individuals with self-reported AD/asthma. The primary outcome was to assess WPAI in each study cohort; secondary outcomes included assessing HRQoL. Results Among the analyzed individuals (AD, N = 957 in 2021; asthma, N = 746 in 2020), approximately half had ≥ 1 additional T2I comorbidity (hay fever, food allergy, asthma/AD, nasal polyps). Both cohorts had substantial overall WPAI (26.6–28.9% of patients). In the AD cohort, individuals with one, two, or three additional T2I comorbidities experienced 4.7%, 5.5%, and 12.1% more overall work impairment, respectively, than those with no comorbidities; the corresponding differences in the asthma cohort were 6.7%, 12.5%, and 13.9%, respectively. Concurrently, several components of HRQoL worsened progressively as the number and burden of T2I comorbidities increased. Conclusion Given that there is considerable correlation between the number of T2I comorbidities and WPAI and HRQoL, comprehensive management of T2I diseases may be crucial for patient care.

Allergy Asthma and Clinical Immunology
Hiroshima University (JP), Teikyo University Hospital (JP), Sanofi (Japan) (JP), Teikyo University (JP)
Sanofi K.K.
Good health and well-being
Dermatology and Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon